US 12,263,157 B2
Aldosterone synthase inhibitors for treating chronic kidney disease
Lisa V. Cronin, Grand Island, NY (US); Sibylle Jenny Hauske, Mannheim (DE); and Hartmut Ruetten, Ingelheim am Rhein (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Dec. 13, 2022, as Appl. No. 18/079,904.
Claims priority of provisional application 63/289,177, filed on Dec. 14, 2021.
Prior Publication US 2023/0181538 A1, Jun. 15, 2023
Int. Cl. A61K 31/4188 (2006.01); A61K 31/4709 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/4188 (2013.01) [A61K 31/4709 (2013.01); A61P 13/12 (2018.01)] 15 Claims
 
1. A method for treating a patient with chronic kidney disease (CKD), the method comprising administering compound 29A to the patient

OG Complex Work Unit Chemistry
wherein compound 29A is administered once daily in an amount of 3 mg, 10 mg or 20 mg, and
wherein the treatment provides an improvement in albumin creatinine ratio (UACR) measured in First Morning Void (FMV) urine.